News

The trial demonstrates the sustained effect of Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor, on reducing the risk of cardiovascular events and sustained vascular and metabolic benefits

The drug, a novel small-molecule activator of cardiac myosin, will be tested in a double-blind placebo-controlled trial in healthy volunteers aimed at testing its safety and tolerability. The

Litigation regarding the patents of the drug is still ongoing, but the companies have decided to go ahead and sell the generic version of the drug without the

Studies show CTCE-0214, the company’s second lead product, can multiply the number of stem cells and related progenitor cell subsets from human cord blood through a process called

EOquin has already shown encouraging activity and safety in superficial bladder cancer in phase I and phase II studies performed in 68 patients with multiple, recurrent disease. Patients

The development contract will have an initial extendable term of one year and provide a dedicated team of scientists from Cirrus Pharmaceuticals. The relationship has been established to

The company says that the liver and lung cancer studies, which are detailed in the journals Hepatology and Cancer Research, respecively, confirm and extend the broad potential of

This approval was gained through the mutual recognition procedure (MRP), under which Labopharm has reached agreement with the 22 countries on a common product label. The MRP will

The FDA has questioned whether CIP-Isotretinoin should be filed under a new drug application (NDA) since it considers the drug eligible for submission as an abbreviated new drug